Table 2.

Patient profiles, treatment, response, and adverse events of ESRD group.

Patient	Age	Primary site	Therapy	Combination	Line	Response	OS (months)	Status	Hematologic AE	Other AE
1	58	Right renal pelvis	Atezolizumab	Paclitaxel	3	PD	8.05	AWD	Gr.4 neutropenia Gr.3 anemia Gr.1 thrombocytopenia	Gr.1 hepatitis Gr.1 anorexia Gr.1 fatigue
2	79	Left ureter	Pembrolizumab	–	1	PR	4.80	AWD	Gr.2 anemia	Gr.2 ascites
3	82	Left renal pelvis and ureter	Pembrolizumab	Gemcitabine	1	PD	0.72	DOD	Gr.3 neutropenia Gr.3 anemia Gr.3 thrombocytopenia	–
4	69	Left renal pelvis	Pembrolizumab	–	1	PD	5.85	DOD	Gr.2 anemia	Gr.1 hepatitis Gr.3 anorexia
5	68	Right renal pelvis	Nivolumab	Gemcitabine	1	PR	12.16	AWD	Gr.3 neutropenia Gr.4 anemia Gr.2 thrombocytopenia	Gr.1 hepatitis Gr.3 ascites
6	63	Left renal pelvis	Nivolumab	–	3	PD	0.23	DOD	Gr.2 anemia Gr.1 thrombocytopenia	Gr.4 CRS
7	45	Right renal pelvis and bladder	Atezolizumab	Paclitaxel	2	SD	19.68	AWD	Gr.4 anemia	–
8	65	Right renal pelvis	Pembrolizumab	–	2	PR	27.17	AWD	Gr.2 neutropenia Gr.2 anemia Gr.1 thrombocytopenia	Gr.2 eczema
9	66	Right renal pelvis	Atezolizumab	–	1	PR	15.54	AWD	Gr.4 neutropenia Gr.4 anemia Gr.1 thrombocytopenia	Gr.3 TB peritonitis Gr.4 TEN
10	74	Bladder	Pembrolizumab	–	2	PR	14.26	AWD	Gr.3 anemia Gr.1 thrombocytopenia Gr.2 anorexia	Gr.2 fatigue
11	35	Bladder	Pembrolizumab	–	1	PR	4.63	AWD	Gr.2 neutropenia Gr.2 anemia Gr.1 thrombocytopenia	–

OS, overall survival; AE, adverse event; PD, progressive disease; PR, partial response; SD, stable disease; AWD, alive with disease; DOD, dead of disease; Gr, grade; CRS, cytokine release syndrome; TB, tuberculosis; TEN, toxic epidermal necrolysis.